Elranatamab is a bispecific antibody used to treat adults with relapsed or refractory multiple myeloma. Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.
- Mechanism
- Curator reviewed · 4 references
BCMA is a B cell maturation antigen that binds several ligands to activate various survival signalling pathways, including NF-kappa B, STAT3, ERK1/2, and AKT/PI3K signalling pathways. It is often overexpressed in malignant plasma B cells, including multiple myeloma cells, making it a promising therapeutic target for T-cell engaging antibodies. Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody. It binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA-expressing cells. Elranatamab activated T-cells, caused pro-inflammatory cytokine release, and resulted in multiple myeloma cell lysis.
- Primary indication
- Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma.Curator reviewed · 4 structured indications
- Formula / weight
- C6440H9958N1738O2010S49 · 148500.0 Da (approximate)
- First approval
- Canada, 2023 · United States, 2023 · European Union, 2024
- Also known as
- ANTI-CD3/ANTI-BCMA BISPECIFIC MONOCLONAL ANTIBODY PF-06863135 · B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB · IMMUNOGLOBULIN G2 (224-ARGININE,265-ALANINE,330-SERINE,331-SERINE), ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .GAMMA.2-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .KAPPA.-CHAIN, (223->217')(2 · IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN CD3E (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN)), HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE WITH IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS-TUMOR NECROSIS FACTO
- Code names
- PF-06863135 · RN-613
- Brand names
Resolves to
What you can answer from here — as of October 11, 2024
Which drugs share a target with Elranatamab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account